Rachel E. Adams
· Professor of English and Comparative LiteratureColumbia University · Joint Programs
Active 1946–2026
Academic metrics are sourced from OpenAlex and public funding records; values may differ from Google Scholar.
Research topics
- Medicine
- Internal medicine
- Computer Science
- Emergency medicine
- Sociology
- Political Science
- Law
- Social psychology
- Virology
- Public relations
Selected publications
The Lancet · 2021 · 1078 citations
The Lancet · 2022 · 382 citations
BACKGROUND: Casirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike glycoprotein, blocking viral entry into host cells. We aimed to evaluate the efficacy and safety of casirivimab and imdevimab administered in combination in patients admitted to hospital with COVID-19. METHODS: RECOVERY is a randomised, controlled, open-label platform trial comparing several possible treatments with usual care in pa…
The Lancet. Gastroenterology & hepatology · 2020 · 180 citations
BACKGROUND: Radical surgery via total mesorectal excision might not be the optimal first-line treatment for early-stage rectal cancer. An organ-preserving strategy with selective total mesorectal excision could reduce the adverse effects of treatment without substantially compromising oncological outcomes. We investigated the feasibility of recruiting patients to a randomised trial comparing an organ-preserving strategy with total mesorectal excision. METHODS: TREC was a randomised, open-label f…
The Lancet · 2023 · 128 citations
BACKGROUND: Low-dose corticosteroids have been shown to reduce mortality for patients with COVID-19 requiring oxygen or ventilatory support (non-invasive mechanical ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation). We evaluated the use of a higher dose of corticosteroids in this patient group. METHODS: This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing multiple possible treatments in pati…
The Lancet Diabetes & Endocrinology · 2023 · 38 citations
BACKGROUND: Empagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess its safety and efficacy in patients admitted to hospital with COVID-19. METHODS: In the randomised, controlled, open-label RECOVERY trial, several possible treatments are compared with usual care in patients hospitalised with COVID-19. In this analysis, we assess eligible and consenting adults who were randomly allo…
Frequent coauthors
- 1100 shared
Christopher J. Gordon
Woolcock Institute of Medical Research
- 996 shared
K. Robinson
University of Nottingham
- 796 shared
Helen M. Dewey
University of Melbourne
- 792 shared
Julie Bernhardt
University of Melbourne
- 784 shared
L. D. Smith
UCL Biomedical Research Centre
- 776 shared
David James
University of Nottingham
- 776 shared
Nick Wilson
Edinburgh Royal Infirmary
- 776 shared
Mary Matthews
Philadelphia VA Medical Center
Education
FRCR, Clinical Oncology
Royal College of Radiologists
MRCP, Medicine
Royal College of Physicians
BM BS, Medicine
University of Nottingham
B.Med.Sci, Medicine
University of Nottingham
- 2007
MD, Medicine
Cardiff University
Similar researchers at Columbia University
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Rachel E. Adams
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup